Home

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D; Antimicrobial Agents & Chemotherapy (Feb 2012)

Source: Antimicrob Agents Chemother

Tags:

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis

Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S; New England Journal of Medicine (NEJM) 366 (13), 1181-9 (Mar 2012)

Source: N Engl J Med

Tags:

Psoriasis

Briakinumab May Be Safe and Effective in Patients With Moderate to Severe Psoriasis

Presented at AAD

Source: DGNews

Tags:

briakinumab

Psoriasis

By John Schieszer

Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers

Chládek J, S?imková M, Vanec?ková J, Hroch M, Vávrová J, Hulek P; Journal of the European Academy of Dermatology and Venereology (Aug 2012)

Source: J Eur Acad Dermatol Venereol

Tags:

Page 27 of 48

CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis

Briakinumab May Be Safe and Effective in Patients With Moderate to Severe Psoriasis

Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers

Main Menu

Statistics

Most Read Content